N-异丙基-1-吡唑烷甲酰胺 | 124072-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: N-异丙基-1-吡唑烷甲酰胺
• 英文名称: Pyrazolidine-1-carboxylic acid isopropylamide
• 英文别名: N-Isopropylpyrazolidine-1-carboxamide；N-propan-2-ylpyrazolidine-1-carboxamide
• CAS: 124072-92-0
• 化学式: C₇H₁₅N₃O
• 分子量: 157.216
• InChiKey: AMOCDAHKAWUHGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-叔丁氧羰基-L-丙氨酸 、 N-异丙基-1-吡唑烷甲酰胺 在 N-甲基吗啉 、 氯甲酸异丁酯 作用下， 生成 Boc-L-Ala-AzaPro-NHiPr
  参考文献：
  名称：

  The couple Pro/AzaPro : A means of β-turn formation control synthesis and conformation of two AzaPro-containing dipeptides

  摘要：

  On the basis of two synthesized AzaPro-containing dipeptides. the conformational influence of the azaproline residue (a nitrogen atom is substituted for the Pro-CH(alpha)) on the beta-turn occurrence was tested according to its relative position in the azadipeptide sequence.

  DOI：

  10.1016/s0040-4039(00)79134-9
• 作为产物：
  描述：

  2-Isopropylcarbamoyl-pyrazolidine-1-carboxylic acid benzyl ester 在 palladium on activated charcoal 氢气 作用下， 以 异丙醇 为溶剂， 生成 N-异丙基-1-吡唑烷甲酰胺
  参考文献：
  名称：

  The couple Pro/AzaPro : A means of β-turn formation control synthesis and conformation of two AzaPro-containing dipeptides

  摘要：

  On the basis of two synthesized AzaPro-containing dipeptides. the conformational influence of the azaproline residue (a nitrogen atom is substituted for the Pro-CH(alpha)) on the beta-turn occurrence was tested according to its relative position in the azadipeptide sequence.

  DOI：

  10.1016/s0040-4039(00)79134-9

文献信息

• New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0300189A2

  公开（公告）日：1989-01-25

  A compound of the formula : wherein R1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl,hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula : in which R5 is hydrogen or acyl and R6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R2 is hydrogen or lower alkyl; or R1 and R2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R3 is hydrogen or lower alkyl; and R4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.

  一种式如下的化合物 其中 R1 是低级烷基，可任选被选自以下组别的取代基取代：酰基、羟基、低级烷氧基、芳基、低级烷硫基和一个式......的基团： 其中 R5 为氢或酰基，且 R6 是氢或低级烷基；芳基；或被选自低级烷基和酰基的取代基任选取代的氨基；以及 R2 是氢或低级烷基；或 R1 和 R2 与所连接的氮原子一起形成杂环基团，该杂环基团可任选被选自由低级烷基、羟基（低级）烷基、低级烷氧基（低级）烷基、酰基（低级）烷基、氧代和酰基组成的取代基取代； R3 是氢或低级烷基；和 R4 是低级烷基； 及其药学上可接受的盐、制备工艺和包含这些成分的药物组合物。
• US4921855A
  申请人：——

  公开号：US4921855A

  公开（公告）日：1990-05-01
• US5142048A
  申请人：——

  公开号：US5142048A

  公开（公告）日：1992-08-25
• US5223489A
  申请人：——

  公开号：US5223489A

  公开（公告）日：1993-06-29